A homozygous stop-gain variant in ARHGAP42 is associated with childhood interstitial lung disease, systemic hypertension, and immunological findings.

MLA

Li, Qifei, et al. “A Homozygous Stop-Gain Variant in ARHGAP42 Is Associated with Childhood Interstitial Lung Disease, Systemic Hypertension, and Immunological Findings.” PLoS Genetics, vol. 17, no. 7, July 2021, p. e1009639. EBSCOhost, https://doi.org/10.1371/journal.pgen.1009639.

APA

Li, Q., Dibus, M., Casey, A., Yee, C. S. K., Vargas, S. O., Luo, S., Rosen, S. M., Madden, J. A., Genetti, C. A., Brabek, J., Brownstein, C. A., Kazerounian, S., Raby, B. A., Schmitz-Abe, K., Kennedy, J. C., Fishman, M. P., Mullen, M. P., Taylor, J. M., Rosel, D., & Agrawal, P. B. (2021). A homozygous stop-gain variant in ARHGAP42 is associated with childhood interstitial lung disease, systemic hypertension, and immunological findings. PLoS Genetics, 17(7), e1009639. https://doi.org/10.1371/journal.pgen.1009639

Chicago

Li, Qifei, Michal Dibus, Alicia Casey, Christina S K Yee, Sara O Vargas, Shiyu Luo, Samantha M Rosen, et al. 2021. “A Homozygous Stop-Gain Variant in ARHGAP42 Is Associated with Childhood Interstitial Lung Disease, Systemic Hypertension, and Immunological Findings.” PLoS Genetics 17 (7): e1009639. doi:10.1371/journal.pgen.1009639.